Get the Stockscreener App
93.51
1.42%
1.31
After Hours:
93.50
-0.01
-0.01%
Inhibrx Biosciences Inc stock is traded at $93.51, with a volume of 380.11K.
It is up +1.42% in the last 24 hours and down -13.93% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$92.20
Open:
$95.12
24h Volume:
380.11K
Relative Volume:
0.91
Market Cap:
$1.37B
Revenue:
$1.30M
Net Income/Loss:
$-140.06M
P/E Ratio:
-10.34
EPS:
-9.0441
Net Cash Flow:
$-129.83M
1W Performance:
+4.91%
1M Performance:
-13.93%
6M Performance:
+22.70%
1Y Performance:
+541.80%
1-Day Range:
$91.60
$96.08
1-Week Range:
$85.66
$96.08
52-Week Range:
$13.97
$155.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
93.51 | 1.35B | 1.30M | -140.06M | -129.83M | -9.0441 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Stifel | Buy |
| Jul-23-24 | Initiated | JMP Securities | Mkt Perform |
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
Inhibrx Biosciences BLA Accepted for Ozekibart Chondrosarcoma Therapy - TipRanks
FDA accepts Inhibrx (NASDAQ: INBX) BLA for first chondrosarcoma therapy - Stock Titan
FDA accepts Inhibrx filing for rare bone cancer treatment By Investing.com - Investing.com Australia
FDA accepts Inhibrx Biosciences filing for ozekibart in metastatic chondrosarcoma - Traders Union
Inhibrx Biosciences stock gains after FDA accepts drug filing By Investing.com - Investing.com Australia
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma - PR Newswire
Number of shareholders of Inhibrx Biosciences, Inc. – NASDAQ:INBX - TradingView
(INBX) Risk Channels and Responsive Allocation - Stock Traders Daily
INBX Q1 2026 Earnings: EPS Misses Estimates as Stock Gains on Operational UpdatesRetail Earnings Report - newsline.com
Inhibrx Biosciences (INBX) director receives 15,000 stock options at $95.22 strike - Stock Titan
Inhibrx Biosciences (INBX) director receives grant of 15,000 stock options - Stock Titan
Inhibrx Biosciences (INBX) director granted 15,000 stock options at $95.22 - Stock Titan
Inhibrx Biosciences Holds 2026 Virtual Annual Shareholder Meeting - TipRanks
Inhibrx Biosciences (NASDAQ: INBX) investors approve directors and BDO - Stock Titan
Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $325 - Moomoo
Stifel reiterates Inhibrx Biosciences stock rating on durability data By Investing.com - Investing.com Canada
Inhibrx Biosciences targets research advances at ASCO26 to accelerate new cancer treatments - Traders Union
Inhibrx Biosciences (INBX) Slips 2% as Stock Tests Key Support Amid Biotech VolatilityVolatility Breakout Picks - thelegaladvocate.com
(INBX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Inhibrx Biosciences (INBX) Edges Higher as Stock Holds Above SupportRVOL Spike - The Legal Advocate
INBX Stock Price, Quote & Chart | INHIBRX BIOSCIENCES INC (NASDAQ:INBX) - ChartMill
Inhibrx Biosciences (INBX) Surges Over 5% as Biotech Momentum BuildsCollar Trade - thelegaladvocate.com
How Positive INBRX-106 Phase 2 Data And Narrower Losses At Inhibrx Biosciences (INBX) Have Changed Its Investment Story - Sahm
Inhibrx Biosciences Hits Day Low of $99.70 Amid Price Pressure - MarketsMojo
Inhibrx Biosciences (INBX) price target increased by 66.67% to 255.00 - MSN
Inhibrx Inc stock (US45720L1070): trial update around ozekibart keeps biotech investors watching - AD HOC NEWS
TRANSCENTA-B: Positive Interim Data from ozekibart Mid-stage Study; Greater China Plan Under Evaluation - AASTOCKS.com
Inhibrx Biosciences' INBRX-106 combo tops KEYTRUDA alone in phase 2 cancer study - MSN
Inhibrx Biosciences, Inc.Common Stock (NQ: INBX - The Chronicle-Journal
This biotech stock surges after positive cancer trial results. What to know. - MSN
Liquidity Mapping Around (INBX) Price Events - Stock Traders Daily
Inhibrx cancer treatment shows high response rates in head and neck cancer study - MSN
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $230 - Moomoo
Viking Global holds 1.46M shares in Inhibrx (INBX); amendment removes one reporter - Stock Titan
Perceptive (INBX) reports a 9.99% stake in INHIBRx via Schedule 13G/A - Stock Titan
Inhibrx Biosciences 1Q Loss/Shr $2.15 >INBX - Moomoo
Inhibrx Reports First Quarter 2026 Financial Results - Arizona Daily Sun
Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Raises Target Price to $325 - Moomoo
Inhibrx & Invesco Mortgage Capital Q1 2026 Results - Punjab Kesari English
INBX SWOT Analysis: Financial Challenges and Promising Pipeline Revealed in 10-Q Filing - GuruFocus
Inhibrx Biosciences Reports Strong Phase 2 Response Data For INBRX 106 And Pembrolizumab Combination In Head And Neck Cancer - BioPharma APAC
Inhibrx Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Inhibrx Biosciences (INBX) cuts Q1 2026 loss, boosts cash but ups debt - Stock Titan
Inhibrx Biosciences (INBX) advances ozekibart BLA and INBRX-106 after strong oncology data - Stock Titan
Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study - Insider Monkey
Inhibrx Inc stock (US45720L1070): Biotech firm in Virtus ETF holdings - AD HOC NEWS
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):